177 related articles for article (PubMed ID: 34973408)
1. A drug-in-adhesive anti-onychomycotic nail patch: Influence of drug and adhesive nature on drug release, ungual permeation, in vivo residence in human and anti-fungal efficacy.
Rizi K; Xu K; Begum T; Faull J; Bhakta S; Murdan S
Int J Pharm; 2022 Feb; 614():121437. PubMed ID: 34973408
[TBL] [Abstract][Full Text] [Related]
2. A systematic approach to the formulation of anti-onychomycotic nail patches.
Rizi K; Mohammed IK; Xu K; Kinloch AJ; Charalambides MN; Murdan S
Eur J Pharm Biopharm; 2018 Jun; 127():355-365. PubMed ID: 29530581
[TBL] [Abstract][Full Text] [Related]
3. UV-curable gels as topical nail medicines:In vivo residence, anti-fungal efficacy and influence of gel components on their properties.
Kerai LV; Hilton S; Maugueret M; Kazi BB; Faull J; Bhakta S; Murdan S
Int J Pharm; 2016 Nov; 514(1):244-254. PubMed ID: 27863669
[TBL] [Abstract][Full Text] [Related]
4. Development of ciclopirox nail lacquer with enhanced permeation and retention.
Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
[TBL] [Abstract][Full Text] [Related]
5. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective.
Elsayed MM
J Control Release; 2015 Feb; 199():132-44. PubMed ID: 25481439
[TBL] [Abstract][Full Text] [Related]
6. A preformulation strategy for the selection of penetration enhancers for a transungual formulation.
Palliyil B; Lebo DB; Patel PR
AAPS PharmSciTech; 2013 Jun; 14(2):682-91. PubMed ID: 23572254
[TBL] [Abstract][Full Text] [Related]
7. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis.
Khattab A; Shalaby S
AAPS PharmSciTech; 2018 Apr; 19(3):1048-1060. PubMed ID: 29138987
[TBL] [Abstract][Full Text] [Related]
8. UV-curable gel formulations: Potential drug carriers for the topical treatment of nail diseases.
Kerai LV; Hilton S; Murdan S
Int J Pharm; 2015 Aug; 492(1-2):177-90. PubMed ID: 26187167
[TBL] [Abstract][Full Text] [Related]
9. Application of Hansen Solubility Parameters to predict drug-nail interactions, which can assist the design of nail medicines.
Hossin B; Rizi K; Murdan S
Eur J Pharm Biopharm; 2016 May; 102():32-40. PubMed ID: 26924329
[TBL] [Abstract][Full Text] [Related]
10. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
[TBL] [Abstract][Full Text] [Related]
11. Bacterial nanocellulose patches as a carrier for hydrating formulations to improve the topical treatment of nail diseases.
Bellmann T; Luber R; Kischio L; Karl B; Pötzinger Y; Beekmann U; Kralisch D; Wiegand C; Fischer D
Int J Pharm; 2022 Nov; 628():122267. PubMed ID: 36209980
[TBL] [Abstract][Full Text] [Related]
12. Permeation studies of novel terbinafine formulations containing hydrophobins through human nails in vitro.
Vejnovic I; Huonder C; Betz G
Int J Pharm; 2010 Sep; 397(1-2):67-76. PubMed ID: 20620203
[TBL] [Abstract][Full Text] [Related]
13. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
[TBL] [Abstract][Full Text] [Related]
14. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
[TBL] [Abstract][Full Text] [Related]
15. Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers.
Monti D; Tampucci S; Chetoni P; Burgalassi S; Mailland F
J Drugs Dermatol; 2014 Feb; 13(2):143-7. PubMed ID: 24509963
[TBL] [Abstract][Full Text] [Related]
16. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Gupta AK; Fleckman P; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
[TBL] [Abstract][Full Text] [Related]
17.
Kubota-Ishida N; Takei-Masuda N; Kaneda K; Nagira Y; Chikada T; Nomoto M; Tabata Y; Takahata S; Maebashi K; Hui X; Maibach HI
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084749
[TBL] [Abstract][Full Text] [Related]
18. Design and development of a safer non-invasive transungual drug delivery system for topical treatment of onychomycosis.
Pal P; Thakur RS; Ray S; Mazumder B
Drug Dev Ind Pharm; 2015; 41(7):1095-9. PubMed ID: 24980914
[TBL] [Abstract][Full Text] [Related]
19. Microstructural alterations in the onychomycotic and psoriatic nail: Relevance in drug delivery.
Cutrín Gómez E; Anguiano Igea S; Delgado-Charro MB; Gómez Amoza JL; Otero Espinar FJ
Eur J Pharm Biopharm; 2018 Jul; 128():48-56. PubMed ID: 29673870
[TBL] [Abstract][Full Text] [Related]
20. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
